Literature DB >> 25919832

Understanding and managing Cognition in the Depressed Patient.

George I Papakostas, Larry Culpepper.   

Abstract

Cognition is a renewed area of clinical focus in major depressive disorder (MDD). Cognitive problems such as difficulty concentrating and making decisions are common symptoms of MDD, and while these symptoms improve as depressive symptoms improve in some patients, a substantial portion of patients experience cognitive impairment even while euthymic. In turn, impaired cognition hinders restoration of psychosocial functioning, allowing for continued difficulty at work, at home, and in social settings. Therefore, clinicians must routinely measure and manage cognitive functioning in patients with MDD. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25919832     DOI: 10.4088/JCP.13086ah1c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Neuroinflammation Regulates Cognitive Impairment in Socially Defeated Mice.

Authors:  Madeline L Pfau; Scott J Russo
Journal:  Trends Neurosci       Date:  2016-04-26       Impact factor: 13.837

2.  Co-occurring symptoms of attention deficit hyperactivity disorder (ADHD) in a population-based sample of adolescents screened for depression.

Authors:  Astri J Lundervold; Stephen P Hinshaw; Lin Sørensen; Maj-Britt Posserud
Journal:  BMC Psychiatry       Date:  2016-02-25       Impact factor: 3.630

3.  Differential Expression of FosB Proteins and Potential Target Genes in Select Brain Regions of Addiction and Depression Patients.

Authors:  Paula A Gajewski; Gustavo Turecki; Alfred J Robison
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

4.  Discrepancy between objective and subjective cognition in adults with major depressive disorder.

Authors:  Manit Srisurapanont; Sirijit Suttajit; Kanokkwan Eurviriyanukul; Prirada Varnado
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

5.  Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.

Authors:  Maurizio Fava; Takao Okame; Yuki Matsushima; Pamela Perry; Emmanuelle Weiller; Ross A Baker
Journal:  Int J Neuropsychopharmacol       Date:  2017-01-01       Impact factor: 5.176

6.  Neurological Symptoms in Palliative Care Patients.

Authors:  Johanna Anneser; Victoria Arenz; Gian Domenico Borasio
Journal:  Front Neurol       Date:  2018-04-25       Impact factor: 4.003

7.  A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors:  G I Papakostas; K Johe; H Hand; A Drouillard; P Russo; G Kay; R Kashambwa; B Hoeppner; M Flynn; A Yeung; M A Martinson; M Fava
Journal:  Mol Psychiatry       Date:  2019-01-09       Impact factor: 15.992

Review 8.  GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?

Authors:  Becky Inkster; Gwyneth Zai; Gemma Lewis; Kamilla W Miskowiak
Journal:  Transl Psychiatry       Date:  2018-10-11       Impact factor: 6.222

Review 9.  A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.

Authors:  Bernhard T Baune; Mélanie Brignone; Klaus Groes Larsen
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.